Last updated: September 8, 2026
CINQAIR, or reslizumab, is Teva Pharmaceuticals’ intravenous anti-IL-5 biologic for adults with severe eosinophilic asthma. The product has a narrow commercial position because it requires weight-based intravenous administration every four weeks and competes with more convenient subcutaneous biologics, including Nucala, Fasenra, and Dupixent.
CINQAIR’s principal commercial risks are limited addressable demand, infusion-center administration, competition from longer-acting therapies, and the absence of a broad label beyond severe eosinophilic asthma. Teva has not consistently reported CINQAIR as a standalone revenue line, preventing a reliable current-product revenue estimate from public filings.
What is CINQAIR approved to treat?
CINQAIR is approved in the United States as an add-on maintenance treatment for patients aged 18 years and older with severe asthma characterized by an eosinophilic phenotype. It is not indicated for acute bronchospasm or status asthmaticus.
| Attribute |
CINQAIR |
| Active ingredient |
Reslizumab |
| Sponsor |
Teva Pharmaceuticals |
| Biologic class |
Anti-interleukin-5 monoclonal antibody |
| FDA approval |
March 23, 2016 |
| FDA application |
BLA 761033 |
| Administration |
Intravenous infusion |
| Dose |
3 mg/kg every four weeks |
| Approved population |
Adults with severe eosinophilic asthma |
| Primary target |
IL-5 |
| Main commercial alternatives |
Nucala, Fasenra, Dupixent, Xolair |
| Acute-rescue use |
Not approved |
Reslizumab binds to interleukin-5, a cytokine involved in eosinophil growth, maturation, recruitment, and survival. Its clinical value is concentrated in patients whose asthma remains uncontrolled despite high-dose inhaled corticosteroid-based therapy and whose disease is associated with elevated eosinophils. [1]
How does CINQAIR compare with competing biologics?
CINQAIR is disadvantaged by its route of administration. Most competing severe-asthma biologics are delivered subcutaneously, allowing administration in the home or through less resource-intensive clinical settings.
| Product |
Active ingredient |
Target or mechanism |
Administration |
Typical dosing interval |
Key commercial advantage |
| CINQAIR |
Reslizumab |
Anti-IL-5 |
IV infusion |
Every four weeks |
Weight-based anti-IL-5 exposure |
| Nucala |
Mepolizumab |
Anti-IL-5 |
Subcutaneous |
Every four weeks, with some indications using longer intervals |
Established eosinophilic-asthma franchise |
| Fasenra |
Benralizumab |
Anti-IL-5 receptor alpha |
Subcutaneous |
Every four weeks initially, then every eight weeks |
Extended maintenance interval |
| Dupixent |
Dupilumab |
IL-4 receptor alpha |
Subcutaneous |
Every two weeks or four weeks, depending on indication and patient factors |
Broad respiratory and immunology label |
| Xolair |
Omalizumab |
Anti-IgE |
Subcutaneous |
Every two or four weeks |
Long-established allergic-asthma positioning |
Fasenra’s eight-week maintenance schedule and Dupixent’s broader respiratory indications create structural pressure on CINQAIR. Nucala is the closest commercial comparator because both products directly inhibit the IL-5 pathway, but Nucala avoids infusion-center administration.
CINQAIR can remain relevant for patients who respond to IL-5 blockade and are treated in specialist centers, particularly where clinicians prefer weight-based dosing or where prior subcutaneous biologics have produced inadequate control. Those advantages have not offset the convenience gap in the broader market.
What is the financial trajectory of CINQAIR?
Public financial data do not support a precise current revenue series for CINQAIR. Teva has reported the product within broader specialty or respiratory categories in certain filings rather than maintaining a consistently disclosed standalone revenue line.
The commercial trajectory is best characterized as a limited-scale specialty product rather than a major growth platform. CINQAIR launched into a severe-asthma market that already included established biologics and then faced intensified competition from products with broader labels, self-administration, and longer dosing intervals.
Revenue trajectory
CINQAIR’s economic profile has four defining characteristics:
- The eligible population is narrow because the label is limited to adults with severe eosinophilic asthma.
- Treatment is administered by IV infusion, creating facility, staffing, and scheduling costs.
- The product is dosed by body weight, which increases drug usage in heavier patients but also raises payer budget impact.
- Teva’s public reporting has not identified CINQAIR as a material standalone revenue contributor in recent annual disclosures. [2]
The product therefore has limited influence on Teva’s consolidated financial results compared with larger assets such as Austedo, Ajovy, Copaxone, and generic medicines. Its financial value is more relevant as an existing marketed biologic with manufacturing and commercial infrastructure than as a major future growth driver.
Revenue exposure under competitive pressure
CINQAIR revenue is exposed to substitution at several points in the treatment pathway:
- New biologic starts can favor subcutaneous alternatives.
- Existing CINQAIR patients may switch to longer-interval products.
- Payers can use formulary controls to steer patients toward preferred biologics.
- Infusion centers can favor products with simpler administration or stronger reimbursement economics.
- Broad-label competitors can capture patients with overlapping atopic dermatitis, chronic rhinosinusitis with nasal polyps, or other type 2 inflammatory diseases.
When does CINQAIR lose biologic exclusivity?
CINQAIR received 12 years of FDA reference-product exclusivity under the Biologics Price Competition and Innovation Act. Based on the March 23, 2016 approval date, the principal U.S. biologic exclusivity period is expected to run through March 23, 2028, subject to statutory and regulatory calculations.
Biologic exclusivity does not eliminate patent-based barriers. It prevents FDA approval of a biosimilar before the applicable exclusivity period ends, but separate patents may expire earlier or later. A biosimilar applicant may begin portions of the development and approval process before the exclusivity date, subject to the statutory framework.
| Milestone |
Date or status |
| FDA approval |
March 23, 2016 |
| Twelve-year reference-product exclusivity |
Expected to expire March 23, 2028 |
| Earliest practical biosimilar competition |
Potentially after the exclusivity and patent landscape are assessed |
| Interchangeable biosimilar status |
None publicly identified |
| Small-molecule generic pathway |
Not applicable |
The FDA Purple Book, rather than the Orange Book, is the principal FDA resource for reference biologics and biosimilar products. CINQAIR should not be analyzed under the same listing framework used for conventional small-molecule drugs. [3]
What patents protect CINQAIR?
CINQAIR’s protection is more complex than a single Orange Book patent expiry. Reslizumab is a monoclonal antibody, so relevant rights can include composition-of-matter claims, antibody sequence claims, methods of treating eosinophilic disease, manufacturing processes, formulations, and delivery-related claims.
Publicly available FDA materials do not provide a conventional Orange Book patent table for CINQAIR. The absence of an Orange Book listing does not establish that no patent rights exist. It means that patent analysis must examine U.S. Patent and Trademark Office records, assignment data, continuation practice, and litigation databases separately from the FDA drug-label record.
Formulation and manufacturing protection
The most commercially relevant non-regulatory barriers may involve:
- Production of the reslizumab antibody in a controlled biologic manufacturing process.
- Purification and viral-clearance steps.
- Stability and storage conditions.
- High-concentration or ready-to-use formulations.
- Comparability data required for a biosimilar applicant.
- Process changes made after approval.
These rights can increase the cost and timing of biosimilar entry, but they do not necessarily create the same binary entry barrier associated with a valid, unexpired composition patent.
Has CINQAIR faced Paragraph IV challenges?
Paragraph IV certifications apply to abbreviated new drug applications for small-molecule products under the Hatch-Waxman Act. CINQAIR is a biologic licensed under a BLA, so a conventional Paragraph IV generic challenge is not the expected pathway.
A competing reslizumab product would generally proceed through the biosimilar framework under the Public Health Service Act. The legal process involves patent-information exchanges and potential patent litigation, but it is not identical to an ANDA Paragraph IV case.
No publicly established biosimilar litigation campaign against CINQAIR has created a widely recognized near-term entry event. The principal competitive threat remains therapeutic substitution by other asthma biologics rather than an imminent reslizumab biosimilar launch.
What is the litigation status of CINQAIR?
There is no widely reported, market-defining U.S. patent litigation campaign that currently determines CINQAIR’s commercial outlook. The absence of a major disclosed case reduces immediate litigation-driven entry risk, but it does not eliminate future biosimilar patent disputes.
Potential litigation issues could include:
- Whether a biosimilar infringes antibody or sequence claims.
- Whether method-of-treatment claims cover eosinophilic asthma use.
- Whether manufacturing patents are valid and enforceable.
- Whether formulation or stability claims materially delay approval or launch.
- Whether a biosimilar sponsor seeks a launch before all asserted patents expire.
The strongest entry barrier is likely to be regulatory exclusivity combined with the technical difficulty of developing a comparable IV monoclonal antibody, rather than a known late-expiring product patent.
What generic or biosimilar launch scenarios exist?
Scenario 1: No near-term biosimilar launch
CINQAIR’s limited market size may reduce the incentive for a biosimilar developer to invest in a product requiring specialized IV manufacturing and a narrow commercial strategy. Competition would continue to come from Nucala, Fasenra, Dupixent, and other asthma biologics.
Scenario 2: Post-2028 biosimilar entry
A biosimilar could enter after the reference-product exclusivity period, subject to patent resolution and FDA approval. Entry would likely target hospital systems, specialty pharmacies, and payers seeking lower-cost IL-5 pathway treatment.
Scenario 3: Authorized or partnered biologic competition
A regional or specialty manufacturer could pursue a development or commercialization partnership rather than an independent U.S. launch. The commercial case would depend on manufacturing cost, contracting access, and the ability to compete against established products with broader indications.
How strong is the CINQAIR patent estate?
CINQAIR’s overall protection is best rated as moderate-to-limited from a commercial perspective.
| Protection category |
Assessment |
| FDA biologic exclusivity |
Material through approximately March 2028 |
| Orange Book protection |
Not the applicable primary framework |
| Biosimilar development complexity |
Moderate to high |
| Product differentiation |
Limited |
| Formulation and manufacturing barriers |
Potentially meaningful but not independently determinative |
| Method-of-use protection |
Relevant only within the approved and enforceable scope |
| Near-term litigation barrier |
No publicly established market-defining campaign |
| Long-term competitive durability |
Weakened by subcutaneous and broader-label competitors |
CINQAIR has regulatory protection, but its commercial durability is weaker than that of biologics with multiple indications, home administration, or extended dosing intervals.
What licensing deals affect CINQAIR?
Teva obtained CINQAIR through its acquisition of Cephalon in 2011. Reslizumab had been developed through the Cephalon pipeline after the company acquired rights and development assets associated with the antibody program. The acquisition gave Teva control of the asset, development program, and commercialization rights.
No major subsequent licensing transaction has publicly repositioned CINQAIR as a high-growth asset. Teva’s strategic focus has shifted toward higher-growth specialty medicines, including central nervous system, immunology, and newer specialty launches. CINQAIR has not occupied the same strategic tier in public investor communications. [2]
What is the FDA and global regulatory status of CINQAIR?
CINQAIR remains an FDA-approved biologic for adult severe eosinophilic asthma. Its European product name is Cinqaero. The global commercial footprint is narrower than that of products with multiple respiratory and immunology indications.
Regulatory limitations include:
- Adult-only U.S. indication.
- No approval for acute asthma exacerbations.
- No broad chronic obstructive pulmonary disease indication.
- No pediatric U.S. indication in the original label.
- IV administration requiring healthcare-professional oversight.
- Anaphylaxis risk requiring observation and treatment capability. [1]
These factors reduce the product’s ability to expand beyond its original specialist market.
Key Takeaways
- CINQAIR is an IV anti-IL-5 biologic for adults with severe eosinophilic asthma.
- Its expected 12-year U.S. biologic exclusivity period runs through approximately March 23, 2028.
- Conventional Paragraph IV generic litigation is not the relevant entry framework because CINQAIR is a biologic.
- No major publicly established biosimilar litigation campaign currently defines its market outlook.
- The product’s principal weakness is administration: IV infusion every four weeks versus subcutaneous and longer-interval competitors.
- Teva does not provide a consistently reported, standalone current revenue line for CINQAIR.
- CINQAIR is unlikely to become a major Teva growth driver without label expansion, substantial contracting gains, or a meaningful change in the severe-asthma treatment landscape.
- Biosimilar entry after the exclusivity period is possible, but market size and manufacturing complexity may limit commercial incentive.
- Competitive substitution from Nucala, Fasenra, Dupixent, and Xolair is a more immediate risk than generic-style erosion.
FAQs About CINQAIR Patent and Market Risk
Is CINQAIR the same drug as Cinqaero?
Yes. Cinqaero is the European trade name for reslizumab, while CINQAIR is the U.S. brand name.
Can a generic company copy CINQAIR?
Not through a conventional ANDA. Reslizumab is a biologic, so a competitor would generally pursue a biosimilar application under the Public Health Service Act.
Does CINQAIR have Orange Book patents?
The Orange Book is not the principal FDA patent resource for CINQAIR because it is licensed as a biologic. The relevant analysis requires Purple Book, patent, assignment, and litigation records.
Why has CINQAIR struggled against Nucala?
Both products target the IL-5 pathway, but Nucala is administered subcutaneously. CINQAIR requires weight-based IV infusion every four weeks, which creates greater treatment burden and site-of-care cost.
Will CINQAIR revenue materially affect Teva after 2028?
CINQAIR is not publicly positioned as a major Teva revenue driver. Its post-exclusivity erosion would likely have a limited effect on consolidated Teva results, although the impact could be material to the product’s respiratory franchise and any external commercialization partner.
References
-
U.S. Food and Drug Administration. (2016). CINQAIR (reslizumab) injection, for intravenous use: Prescribing information. FDA.
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F for the year ended December 31, 2023. Teva Pharmaceuticals.
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.
